Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1682
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17029684 | NEXT-GENERATION SEQUENCING ASSAY FOR GENOMIC CHARACTERIZATION AND MINIMAL RESIDUAL DISEASE DETECTION IN THE BONE MARROW, PERIPHERAL BLOOD, AND URINE OF MULTIPLE MYELOMA AND SMOLDERING MYELOMA PATIENTS | Non-Final OA | The Broad Institute, Inc. |
| 19087361 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY | Non-Final OA | Myriad Genetics, Inc. |
| 18008053 | IMMUNOGENIC RETROELEMENTS AND THEIR USE IN CANCER THERAPY | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18316719 | ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA | Non-Final OA | Oregon Health & Science University |
| 18087426 | Methods and Compositions for Diagnosis and Treatment of Disorders in Pets | Final Rejection | Hill's Pet Nutrition, Inc. |
| 17907774 | COMPOSITIONS AND METHODS FOR DETECTING BCL2L14 AND ETV6 GENE FUSIONS FOR DETERMINING INCREASED DRUG RESISTANCE | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 16973414 | METHOD FOR DETECTING A TANDEM REPEAT | Non-Final OA | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE |
| 17558626 | SNP MARKERS OF DRUG REDUCED SUSCEPTIBILITY RELATED EVOLUTIONARY BRANCHES OF CLOSTRIDIUM DIFFICILE, METHOD FOR IDENTIFYING STRAIN CATEGORY, AND USE THEREOF | Non-Final OA | BGI SHENZHEN |
| 17813647 | METHODS FOR THE COMPREHENSIVE IDENTIFICATION OF ANTIMICROBIAL RESISTANCE MARKERS BY SEQUENCING | Final Rejection | bioMérieux |
| 18423938 | METHODS AND COMPOSITIONS FOR TREATING LIVER CANCER AND LIVER DISEASE | Final Rejection | Active Genomes Expressed Diagnostics Corp |
| 18407073 | KITS AND METHODS FOR DIAGNOSING LUNG CANCER | Non-Final OA | NUCLEIX LTD. |
| 17274126 | BIOMARKERS FOR CANCER THERAPY | Non-Final OA | The Council of the Queensland Institute of Medical Research |
| 18032492 | METHODS FOR TREATMENT OF LUNG CANCERS | Final Rejection | Mirati Therapeutics, Inc. |
| 18280801 | COMPOSITION FOR DIAGNOSING PANCREATIC CANCER | Non-Final OA | ACURASYSBIO CO., LTD. |
| 18546939 | USE OF ABCF1 IN METHODS OF DIAGNOSING AND MONITORING INFLAMMATORY AND/OR AUTOIMMUNE DISEASE | Non-Final OA | MYND Life Sciences Inc. |
| 17576307 | COMPOSITIONS AND METHODS FOR DISCRIMINATING BACTERIAL AND VIRAL INFECTIONS IN A HUMAN SUBJECT | Final Rejection | Cepheid |
| 18093066 | METHODS RELATED TO BRONCHIAL PREMALIGNANT LESION SEVERITY AND PROGRESSION | Final Rejection | HEALTH RESEARCH, INC. |
| 18068517 | COMPANION DIAGNOSTIC BIOMARKERS OF EGFR INHIBITOR | Non-Final OA | KOREA FOOD & DRUG ADMINISTRATION |
| 17904617 | METHOD FOR IMPROVING THE TREATMENT WITH IMMUNE CHECKPOINT BLOCKADE THERAPY | Final Rejection | WORLDWIDE INNOVATIVE NETWORK |
| 17553299 | LIPOSOMAL PREPARATIONS FOR NON-INVASIVE-PRENATAL OR CANCER SCREENING | Final Rejection | SeraCare Life Sciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy